Moderna says its coronavirus vaccine trial produced ‘robust’ immune response in all patients – CNBC

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Ross J Burland FXStreet

Moderna’s potential vaccine to prevent Covid-19 which was first reported to be appearing to be safe back in mid-May, offering a glint of hope, has just been reported by CNBC to have produced neutralizing antibodies in all 45 patients in its early stage human trial.

Key points

Moderna’s potential vaccine to prevent Covid-19 produced neutralizing antibodies in all 45 patients in its early stage human trial, according to newly released data.

The findings provide more promising data that the vaccine may give some protection against the coronavirus.

At 5pm EST, CNBC released a report that started with the opening paragraphs as follows:

Lead paragraphs

Moderna’s potential vaccine to prevent Covid-19 produced a “robust” immune response in all 45 patients in its early stage human trial, providing more promising data that the vaccine may give some protection against the coronavirus, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine.

All 45 patients produced neutralizing antibodies, which scientists believe are important for gaining protection against the virus. In the trial, each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group. Participants received two doses of the potential vaccine.

After two vaccinations, the vaccine elicited a “robust” immune response in all participants in all dose cohorts, Moderna said. The company said the levels of neutralizing antibodies in patients in the high dose group were fourfold higher than in recovered Covid-19 patients.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Market implications

Moderna’s stock rose more than 9% in after-hours trading on the news.

The news could help to push the bulls back into full control on Wall Street whereby they are otherwise vulnerable to bank's guidance and earnings this week.

EUR/USD gains traction to near 1.1800 as tariff uncertainty weighs on US Dollar

The EUR/USD pair holds positive ground around 1.1795 during the early Asian session on Tuesday. The US Dollar weakens against the Euro amid US tariff uncertainty. The release of the US January Producer Price Index report will be in the spotlight later on Friday.

GBP/USD treads water near 1.3500 as BoE-Fed divergence debate stalls

GBP/USD spent Monday spinning in place as market participants await a fresh catalyst to break the pair out of its recent range. The BoE's February hold came with a surprisingly dovish 5-4 split, and UK Consumer Price Index data last week showed inflation easing to 3.0%, reinforcing the case for earlier rate cuts, with most economists now looking to April or March for the next move.

Gold down but not out as key $5,140 support holds

Gold consolidates the advance to monthly top of $5,250 in Tuesday’s Asian trades. The US Dollar finds demand as liquidity returns and risk sentiment recovers, despite US tariffs uncertainty. Gold defends 61.8% Fibo resistance at $5,142 amid the pullback, daily RSI remains bullish.

Top Crypto Losers: BCH, HYPE, PUMP extend losses as Bitcoin drops below $64,000

Altcoins, including Bitcoin Cash, Hyperliquid, and Pump.fun, are leading losses over the last 24 hours as Bitcoin falls below $64,000 on Tuesday. The technical outlook for BCH, HYPE, and PUMP flags downside risk amid broader market selling.

Supreme Court nixes tariffs, Trump teases 15% global tariff

On February 20th, the Supreme Court ruled that Trump’s global tariffs under IEEPA authority were unconstitutional, effectively nullifying the framework. However, the relief was short-lived. Within hours, Trump floated a 15% blanket tariff under an alternative legal authority.

XRP recovers slightly as bearish sentiment dominates crypto market

Ripple is rising above $1.40 at the time of writing on Monday amid fresh tariff-triggered headwinds in the broader cryptocurrency market. The sell-off to $1.33, the token’s intraday low, can be attributed to macroeconomic uncertainty, geopolitical tensions and risk-averse sentiment among other factors.